Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

anti-COVID drug

- PMLiVE

Act-Accelerator outlines plans for longterm COVID-19 control

Its plan highlights key priorities as countries transition to manage the public health issue

- PMLiVE

NHS England hits ten million in autumn COVID-19 booster campaign

Health leaders have warned of a COVID-19 and flu ‘twindemic’ this winter

- PMLiVE

WHO reveals tuberculosis deaths rose due to COVID-19 disruption

An estimated 10.6 million were infected with TB in 2021, an increase of 4.5% from 2020

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

- PMLiVE

Novavax’s COVID-19 vaccine candidate approved for emergency use by FDA as a booster

The authorisation is for those unable to receive an FDA-authorised mRNA bivalent booster

- PMLiVE

Moderna’s Omicron BA.1 booster shows superior antibody response over Spikevax

Data indicates that the superior response is sustained for at least three months

- PMLiVE

New study identifies gene associated with strong immune response to COVID-19 vaccines

Two out of every five people in the UK carry a version of an HLA gene called HLA-DQB1*06

- PMLiVE

Pfizer/BioNTech announce positive early data from trial of BA.4/BA.5 COVID-19 booster

A 30µg dose of the booster demonstrated a ‘substantial increase’ in antibody response

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster approved for emergency use by FDA in children five to 11 years

The doses will be shipped immediately, pending recommendation from the CDC

- PMLiVE

Merck’s sotatercept shows promise as pulmonary arterial hypertension add-on treatment in phase 3 trial

The study met its primary endpoint of a clinically meaningful improvement in six-minute walk distance

- PMLiVE

Shionogi signs licence agreement with MPP for COVID-19 oral antiviral treatment

The agreement aims to increase access to ensitrelvir in low- and middle-income countries

- PMLiVE

InflaRx seeks FDA authorisation for vilobelimab for critically ill COVID-19 patients

A phase 3 study showed that the antibody reduced the all-cause mortality rate after 28 days

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links